Phase 0, Including Microdosing Approaches: Applying the Three Rs and Increasing the Efficiency of Human Drug Development
The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Phase 0 approaches, including microdosing, involve the use of sub-therapeutic exposures to the tested drugs, thus enabling safer, more-relevant, quicker and cheaper first-in-human (FIH) testing. These approaches also have considerable potential to limit the use of animals in human drug development. Recent years have witnessed progress in applications, methodology, operations, and drug development culture. Advances in applications saw an expansion in therapeutic areas, developmental scenarios and scientific objectives, in, for example, protein drug development and paediatric drug development. In the operational area, the increased sensitivity of Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS), expansion of the utility of Positron Emission Tomography (PET) imaging, and the introduction of Cavity Ring-Down Spectroscopy (CRDS), have led to the increased accessibility and utility of Phase 0 approaches, while reducing costs and exposure to radioactivity. PET has extended the application of microdosing, from its use as a predominant tool to record pharmacokinetics, to a method for recording target expression and target engagement, as well as cellular and tissue responses. Advances in methodology include adaptive Phase 0/Phase 1 designs, cassette and cocktail microdosing, and Intra-Target Microdosing (ITM), as well as novel modelling opportunities and simulations. Importantly, these methodologies increase the predictive power of extrapolation from microdose to therapeutic level exposures. However, possibly the most challenging domain in which progress has been made, is the culture of drug development. One of the main potential values of Phase 0 approaches is the opportunity to terminate development early, thus not only applying the principle of 'kill-early-kill-cheap' to enhance the efficiency of drug development, but also obviating the need for the full package of animal testing required for therapeutic level Phase 1 studies. Finally, we list developmental scenarios that utilised Phase 0 approaches in novel drug development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207
Singh, J. (2015) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.162004 · Cited by 893
Morgan, P., Van Der Graaf, P. H., Arrowsmith, J., Feltner, D. E., Drummond, K. S., Wegner, C. D., & Street, S. D. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.020 · Cited by 692
Kummar, S., Kinders, R., Gutierrez, M. E., Rubinstein, L., Parchment, R. E., Phillips, L. R., Ji, J., Monks, A., Low, J. A., Chen, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7681 · Cited by 326
Extrapolation of Adult Data and Other Data in Pediatric Drug-Development Programs
Dunne, J., Rodriguez, W. J., Murphy, M. D., Beasley, B. N., Burckart, G. J., Filie, J. D., Lewis, L. L., Sachs, H. C., Sheridan, P. H., Starke, P., et al. (2011) · Pediatrics · doi:10.1542/peds.2010-3487 · Cited by 318
Bergstr�m, M., Grahn�n, A., & L�ngstr�m, B. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0643-x · Cited by 311
Big physics, small doses: the use of AMS and PET in human microdosing of development drugs
Lappin, G., & Garner, R. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1037 · Cited by 260
Cuzzolin, L., Atzei, A., & Fanos, V. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.5.703 · Cited by 252
Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs
LAPPIN, G., KUHNZ, W., JOCHEMSEN, R., KNEER, J., CHAUDHARY, A., OOSTERHUIS, B., DRIJFHOUT, W., ROWLAND, M., & GARNER, R. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.05.008 · Cited by 241
Extrapolation of Adult Data and Other Data in Pediatric Drug-Development Programs
(2011) · PEDIATRICS · doi:10.1542/peds.2010-3487d · Cited by 224
Off-Label Drug Use in Pediatric Patients
Kimland, E., & Odlind, V (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.26 · Cited by 223
Maeda, K., Ikeda, Y., Fujita, T., Yoshida, K., Azuma, Y., Haruyama, Y., Yamane, N., Kumagai, Y., & Sugiyama, Y. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.142 · Cited by 211
Self-citationNational Cancer Institute (2020) · Definitions · doi:10.32388/48jgaf · Cited by 198
Turteltaub, K. W., Felton, J. S., Gledhill, B. L., Vogel, J. S., Southon, J. R., Caffee, M. W., Finkel, R. C., Nelson, D. E., Proctor, I. D., & Davis, J. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.14.5288 · Cited by 188
Poulin, P., Jones, R. D. O., Jones, H. M., Gibson, C. R., Rowland, M., Chien, J. Y., Ring, B. J., Adkison, K. K., Ku, M. S., He, H., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22550 · Cited by 174
Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Populations
Shaddy, R. E., Denne, S. C., & The Committee on Drugs and Committee on Pediatric Research (2010) · Pediatrics · doi:10.1542/peds.2010-0082 · Cited by 172
Spectroscopic detection of radiocarbon dioxide at parts-per-quadrillion sensitivity
Galli, I., Bartalini, S., Ballerini, R., Barucci, M., Cancio, P., Pas, M. D., Giusfredi, G., Mazzotti, D., Akikusa, N., & Natale, P. D. (2016) · Optica · doi:10.1364/optica.3.000385 · Cited by 166
Vogel, J. S., Turteltaub, K. W., Finkel, R. C., & Nelson, D. E. (1995) · Analytical Chemistry · doi:10.1021/ac00107a714 · Cited by 165
Chapman, K. L., Holzgrefe, H., Black, L. E., Brown, M., Chellman, G., Copeman, C., Couch, J., Creton, S., Gehen, S., Hoberman, A., et al. (2013) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2013.03.001 · Cited by 136
Pediatric Off-Label and Unlicensed Drug Use and Its Implications
Gore, R., Chugh, P. K., Tripathi, C. D., Lhamo, Y., & Gautam, S. (2017) · Current Clinical Pharmacology · doi:10.2174/1574884712666170317161935 · Cited by 125
Bellis, J. R., Kirkham, J. J., Thiesen, S., Conroy, E. J., Bracken, L. E., Mannix, H. L., Bird, K. A., Duncan, J. C., Peak, M., Turner, M. A., et al. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-238 · Cited by 123
Neonatal drug therapy: The first frontier of therapeutics for children
Allegaert, K., & van den Anker, J. N. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.166 · Cited by 104
Microdosing and drug development: past, present and future
Lappin, G., Noveck, R. J., & Burt, T. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.786042 · Cited by 100
Self-citationMicrodosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development
Burt, T., Yoshida, K. J., Lappin, G., Vuong, L. T., John, C. S., de Wildt, S. N., Sugiyama, Y., & Rowland, M. (2016) · Clinical and Translational Science · doi:10.1111/cts.12390 · Cited by 100
Self-citationFailed Pediatric Drug Development Trials
Momper, J., Mulugeta, Y., & Burckart, G. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.142 · Cited by 94
Optical Measurement of Radiocarbon below Unity Fraction Modern by Linear Absorption Spectroscopy
Fleisher, A. J., Long, D. A., Liu, Q., Gameson, L., & Hodges, J. T. (2017) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.7b02105 · Cited by 77
Impact of microdosing clinical study — Why necessary and how useful?
Sugiyama, Y., & Yamashita, S. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.09.010 · Cited by 67
Self-citationCarpenter, A. P., Pontecorvo, M. J., Hefti, F. F., & Skovronsky, D. (2009) · PubMed · Cited by 58
Shingaki, T., Takashima, T., Ijuin, R., Zhang, X., Onoue, T., Katayama, Y., Okauchi, T., Hayashinaka, E., Cui, Y., Wada, Y., et al. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.206425 · Cited by 58
Self-citationA dynamic map for learning, communicating, navigating and improving therapeutic development
Wagner, J., Dahlem, A. M., Hudson, L. D., Terry, S. F., Altman, R. B., Gilliland, C. T., DeFeo, C., & Austin, C. P. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.217 · Cited by 56
Madan, A., O'Brien, Z., Wen, J., O'Brien, C., Farber, R., Beaton, G., Crowe, P., Oosterhuis, B., Garner, R., Lappin, G., et al. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03351.x · Cited by 55
Microdosing: A Critical Assessment of Human Data
Rowland, M. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23290 · Cited by 54
BAUER, M., LANGER, O., DALBIANCO, P., KARCH, R., BRUNNER, M., ABRAHIM, A., LANZENBERGER, R., HOFMANN, A., JOUKHADAR, C., & CARMINATI, P. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.05.007 · Cited by 53
The History of Alternative Test Methods in Toxicology
(2018) · Elsevier eBooks · doi:10.1016/c2016-0-00193-6 · Cited by 50
Phase 0 Microdosing PET Study Using the Human Mini Antibody F16SIP in Head and Neck Cancer Patients
Heuveling, D. A., de Bree, R., Vugts, D. J., Huisman, M. C., Giovannoni, L., Hoekstra, O. S., Leemans, C. R., Neri, D., & van Dongen, G. A. M. S. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.111310 · Cited by 49
Novel strategies for microdose studies using non-radiolabeled compounds
Maeda, K., & Sugiyama, Y. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.02.004 · Cited by 49
Self-citationQuantifying Carbon-14 for Biology Using Cavity Ring-Down Spectroscopy
McCartt, A. D., Ognibene, T. J., Bench, G., & Turteltaub, K. W. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b02054 · Cited by 45
Self-citationOptimising the design of preliminary toxicity studies for pharmaceutical safety testing in the dog
Smith, D., Combes, R. D., Depelchin, O., Jacobsen, S. D., Hack, R., Luft, J., Lammens, L., von Landenberg, F., Phillips, B., Pfister, R., et al. (2004) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2004.10.006 · Cited by 38
Self-citationWang, J. L., Aston, K. W., Limburg, D. C., Ludwig, C., Hallinan, A. E., Koszyk, F. J., Hamper, B. C., Brown, D. L., Graneto, M. J., Talley, J. J., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.07.059 · Cited by 37
Burt, T., John, C. S., Ruckle, J., & Vuong, L. T. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1227786 · Cited by 37
Self-citationPositron emission tomography for use in microdosing studies.
Wagner, C. C., Müller, M., Lappin, G., & Langer, O. (2008) · PubMed · Cited by 36
Pediatric microdose and microtracer studies using 14C in Europe
Turner, M., Mooij, M. G., Vaes, W. H. J., Windhorst, A. D., Hendrikse, N. H., Knibbe, C., Kõrgvee, L. T., Maruszak, W., Grynkiewicz, G., Garner, R. C., et al. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.163 · Cited by 34
Mooij, M. G., van Duijn, E., Knibbe, C. A. J., Windhorst, A. D., Hendrikse, N. H., Vaes, W. H. J., Spaans, E., Fabriek, B. O., Sandman, H., Grossouw, D., et al. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0176-8 · Cited by 33
Ieiri, I., Tsunemitsu, S., Maeda, K., Ando, Y., Izumi, N., Kimura, M., Yamane, N., Okuzono, T., Morishita, M., Kotani, N., et al. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.62 · Cited by 33
Self-citationAFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects
Kaplan, N., Garner, R. C., & Hafkin, B. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.08.019 · Cited by 32
Kratochwil, N. A., Dueker, S. R., Muri, D., Senn, C., Yoon, H., Yu, B. Y., Lee, G., Dong, F., & Otteneder, M. B. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205435 · Cited by 32
Applications of Accelerator Ms in Pediatric Drug Evaluation
Vuong, L., Blood, A. B., Vogel, J. S., Anderson, M., & Goldstein, B. (2012) · Bioanalysis · doi:10.4155/bio.12.173 · Cited by 31
Self-citationEthical Considerations in Conducting Pediatric and Neonatal Research in Clinical Pharmacology
Roth-Cline, M. D., & Nelson, R. M. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150901105146 · Cited by 29
Johnström, P., Bergman, L. B., Varnäs, K., Malmquist, J., Halldin, C., & Farde, L. (2015) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2015.02.001 · Cited by 28
Recommendations toward a human pathway-based approach to disease research
Marshall, L. J., Austin, C. P., Casey, W., Fitzpatrick, S. C., & Willett, C. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.038 · Cited by 28 · cited 2×
“Concerted efforts are now under way to replace animal tests with human-relevant approaches, in order to better protect patients and reduce development costs and animal use in drug development (12).”
BackgroundVlaming, M., van Duijn, E., Dillingh, M. R., Brands, R., Windhorst, A. D., Hendrikse, N. H., Bosgra, S., Burggraaf, J., de Koning, M., Fidder, A., et al. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.131 · Cited by 27
History of the 3Rs in Toxicity Testing: From Russell and Burch to 21st Century Toxicology
Stephens, M. L., & Mak, N. S. (2013) · Royal Society of Chemistry eBooks · doi:10.1039/9781849737920-00001 · Cited by 27
Pharmacokinetic, Dosimetry and Toxicity Study of 177 Lu-EDTMP in Patients: Phase 0/I study
Bal, C. S., Arora, G., Kumar, P., Damle, N., Das, T., Chakraborty, S., Banerjee, S., Venkatesh, M., Zaknun, J. J., & Pillai, M. R. A. (2015) · Current Radiopharmaceuticals · doi:10.2174/1874471008666150313105000 · Cited by 26
Quantifying exploratory low dose compounds in humans with AMS
Dueker, S. R., Vuong, L. T., Lohstroh, P. N., Giacomo, J., & Vogel, J. S. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.10.009 · Cited by 25
Self-citationMicrodosing Studies in Children: A US Regulatory Perspective
Roth-Cline, M. D., & Rm, N. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.165 · Cited by 24
Lead PK Commentary: Predicting Human Pharmacokinetics
Rowland, M., & Benet, L. Z. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22637 · Cited by 24
Sugiyama, Y. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.127 · Cited by 23
Self-citationSuccessful Use of [14C]Paracetamol Microdosing to Elucidate Developmental Changes in Drug Metabolism
Mooij, M. G., van Duijn, E., Knibbe, C. A. J., Allegaert, K., Windhorst, A. D., van Rosmalen, J., Hendrikse, N. H., Tibboel, D., Vaes, W. H. J., & de Wildt, S. N. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0508-6 · Cited by 23
A human microdose study of the antimalarial drug GSK3191607 in healthy volunteers
Okour, M., Derimanov, G. S., Barnett, R., Fernández, E., Ferrer, S. B., Gresham, S., Hossain, M. S., Gamo, F., Koh, G. C. K. W., Pereira, A. I., et al. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13476 · Cited by 13
Self-citationBurt, T., Noveck, R. J., Macleod, D., Layton, A., Rowland, M., & Lappin, G. (2017) · Clinical and Translational Science · doi:10.1111/cts.12464 · Cited by 11
Self-citationBurt, T., MacLeod, D. B., Lee, K. J., Santoro, A., DeMasi, D. K., Hawk, T. C., Feinglos, M. N., Rowland, M., & Noveck, R. J. (2017) · Clinical and Translational Science · doi:10.1111/cts.12477 · Cited by 11
Self-citationCombes, R. D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.02470-7 · Cited by 10
Self-citationKusuhara, H., Takashima, T., Fujii, H., Takashima, T., Tanaka, M., Ishii, A., Tazawa, S., Takahashi, K., Takahashi, K., Tokai, H., et al. (2017) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2017.09.003 · Cited by 8
Self-citationCan positron emission tomography facilitate paediatric drug development?
Zimmer, L. (2008) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00650.x · Cited by 5
Smith, D., Combes, R. D., Descotes, G., Jacobsen, S. D., Hack, R., Kemkowski, J., Krauser, K., Lammens, L., Pfister, R., Phillips, B., et al. (2003) · Toxicology Letters · doi:10.1016/s0378-4274(03)90166-4 · Cited by 2
Self-citation
Research works printed but not linked: 7
- Vuong L.T., 2015, Future Science OA, 2, 1
- Wagner C.C., 2008, Current Opinion in Drug Discovery & Development, 11, 104
- LappinG., WarringtonS., HoneybourneD., SangheraD., DowenS., ListerN., IslamK. & LociuroS. (2007). Concentrations of AR-709 in plasma and key compartments of the lungs after microdosing. [Poster presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA].
- Carpenter A.P., 2009, Quarterly Journal of Nuclear Medicine & Molecular Imaging, 53, 387
- Combes R., 2006, ATLA, 34, 621
- BéruBé K., 2009, ATLA, 37, 89
- Bailey J., 2014, ATLA, 42, 181
Cited by
Limitations of Animal Studies for Predicting Toxicity in Clinical Trials
Van Norman, G. A. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.10.008 · Cited by 732
Phase 0/microdosing approaches: time for mainstream application in drug development?
Burt, T., Young, G. C., Lee, W., Kusuhara, H., Langer, O., Rowland, M., & Sugiyama, Y. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0080-x · Cited by 119
Self-citationMonoplex and multiplex immunoassays: approval, advancements, and alternatives
Ahsan, H. (2021) · Comparative Clinical Pathology · doi:10.1007/s00580-021-03302-4 · Cited by 93
Hou, L., Rong, J., Haider, A., Ogasawara, D., Varlow, C., Schafroth, M. A., Mu, L., Gan, J., Xu, H., Fowler, C. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01459 · Cited by 67
Eke, A. C., Olagunju, A., Best, B. M., Mirochnick, M. H., Momper, J. D., Abrams, E. J., Penazzato, M., Cressey, T. R., & Colbers, A. P. H. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00915-w · Cited by 34
Metadata
- Authors
- Burt, T., Vuong, L. T., Baker, E., Young, G. C., McCartt, A. D., Bergstrom, M., Sugiyama, Y., & Combes, R.
- Affiliations
- Burt Consultancy, LLC, Durham, NC, USA;
- LTV Consulting, Davis, CA, USA;
- Physicians Committee for Responsible Medicine (US)
- GlaxoSmithKline (United Kingdom) (GB)
- Lawrence Livermore National Laboratory (US)
- Department of Pharmacology and PET-centre, Uppsala University, Uppsala, Sweden
- RIKEN (JP)
- Independent Consultant, Norwich, UK
- Corresponding author
- Burt, Tal
- Venue
- Alternatives to Laboratory Animals
- Publisher
- SAGE Publications
- Published
- 2018-12
- Volume
- 46
- Issue
- 6
- Pages
- 335-346
- ISSN
- 0261-1929 (ISSN-L)
- 2632-3559
- OpenAlex
- W2938039109
- Cited by
- 18
- References
- 69
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 4 · 2022: 1 · 2021: 3 · 2020: 6 · 2019: 2
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Alternatives to Laboratory Animals (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Keywords
- microdosing, 3Rs, animal testing reduction, positron emission tomography, target engagement, LC-MS/MS, cavity ring-down spectroscopy, pediatric drug development, drug development efficiency
- MeSH terms
- Drug Development, Animals, Animal Testing Alternatives, Animal Welfare, Chromatography, Liquid, Humans, Animal Experimentation, Positron-Emission Tomography, Tandem Mass Spectrometry
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.